| 19.41 Real-Time Quote |  +0.28 / +1.46%Today’s Change | 10.85 Today|||52-Week Range 20.75 | +61.21% Year-to-Date |
| Pharma M&A: defensive deals May 28 / FT.com | The biggest merger you didn't hear about today May 20 / Fortune |
| Bausch & Lomb - successful outcome May 27 / FT.com | Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal May 20 / FT.com |
| Valeant pays $8.7 billion for Bausch & Lomb May 27 / CNNMoney.com | Yahoo in focus as stocks stick near record highs May 20 / CNNMoney.com |
| Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons May 21 / Fortune | Actavis in talks to buy Warner Chilcott May 10 / FT.com |
| Actavis/Warner Chilcott: simple medicine May 20 / FT.com |
| Previous close | 19.13 |
| Today’s open | 19.09 |
| Day’s range | 18.96 - 19.40 |
| Volume | 576,882 |
| Average volume (3 months) | 6,876,277 |
| Market cap | $4.8B |
| Dividend yield | 2.58% |
| Earnings growth (last year) | +140.30% |
| Earnings growth (this year) | -18.20% |
| Earnings growth (next 5 years) | +1.70% |
| Revenue growth (last year) | -6.86% |
| P/E ratio | -- |
| Price/Sales | 1.18 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| IDXXIDEXX Laboratories I... | -0.15 | -0.18% |
| ENDPEndo Health Solution... | +0.86 | +2.29% |
| ALKSAlkermes Plc | +0.02 | +0.07% |
| SGENSeattle Genetics Inc | +0.39 | +1.16% |
| Next reporting date | August 9, 2013 |
| EPS forecast (this quarter) | $0.85 |
| Annual revenue (last year) | $2.5B |
| Annual profit (last year) | $403.0M |
| Net profit margin | 15.86% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President, Chief Executive Officer & Director Roger M. Boissonneault |
Chief Financial Officer, Director & Executive VP Paul S. Herendeen, MBA |
Corporate headquarters Dublin, Dublin |
.
